Drug company AbbVie has agreed to buy biotech ImmunoGen for $10.1 billion in a fresh bet on one of the most promising new technologies for attacking cancer.ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which work like guided missiles delivering a toxic agent directly to tumors. The technology is among the hottest areas in the pharmaceutical industry. Recent advancements have spread its use to common kinds of cancer such as breast, spawning other multibillion deals.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.731M | |||
| Open | High | Low | Value | Volume |
| 0.2¢ | 0.2¢ | 0.2¢ | $3.509K | 1.754M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 46 | 104890723 | 0.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.2¢ | 54489518 | 26 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| PAB (ASX) Chart |